Published on: June 2026
FORMULATION AND EVALUATION OF TEMOZOLOMIDE ORAL SUSPENSION FOR BRAIN TUMOR THERAPY
Ravindra Narwade Prof. Amol Wadhave Prof. Priya Jaware
Dr. Santosh Payghan
Article Status
Available Documents
Abstract
Keywords: Temozolomide, Oral suspension, Brain tumor, Glioblastoma, Pediatric formulation, Stability study.
How to Cite this Paper
Narwade, R., Wadhave, A. & Jaware, P. (2026). Formulation and Evaluation of Temozolomide Oral Suspension for Brain Tumor Therapy. International Journal of Creative and Open Research in Engineering and Management, <i>02</i>(6). https://doi.org/10.55041/ijcope.v2i6.280
Narwade, Ravindra, et al.. "Formulation and Evaluation of Temozolomide Oral Suspension for Brain Tumor Therapy." International Journal of Creative and Open Research in Engineering and Management, vol. 02, no. 6, 2026, pp. . doi:https://doi.org/10.55041/ijcope.v2i6.280.
Narwade, Ravindra,Amol Wadhave, and Priya Jaware. "Formulation and Evaluation of Temozolomide Oral Suspension for Brain Tumor Therapy." International Journal of Creative and Open Research in Engineering and Management 02, no. 6 (2026). https://doi.org/https://doi.org/10.55041/ijcope.v2i6.280.
Search & Index
References
- Darkes MJM, Plosker GL, Jarvis B. Temozolomide: A review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers. Am J Cancer 2002;1:55-80.
- Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, Maravelis G, et al. Temozolomide with radiation therapy in high grade brain gliomas: Pharmaceuticals considerations and efficacy: A review article. Molecules 2009;14:1561-77.
- Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors. A report from the Children’s Oncology Group. Cancer 2007;110:1542-50.
- Kodawara T, Mizuno T, Taue H, Hashida T, Yano I, Katsura T, et al. Evaluation of stability of temozolomide in solutions after opening the capsule. Yakugaku Zasshi 2009;129:353-7.
- Trissel LA, Zhang Y, Koontz S. Temozolomide stability in extemporaneously compounded oral suspensions. Int J Pharm Compounding 2006;10:396-9.
- Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994;33:9045-51.
- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. for the European Organisation for Research and Treatment of Cancer Brain Tumour. Lancet Oncol 2009; 10:459-66.
- Fontan JE, Mille F, Brion F, Aubin F, Ballereau F, Benoît G, et al. for the Groupe Pédiatrie de la Société Française de Pharmacie Clinique. Drug administration to paediatric inpatient. Arch Pediatr 2004;11:1173-84.
- Eksborg S, Pal N, Kalin M, Palm C, Söderhäll S. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: Can intravenous acyclovir be substituted by oral valacyclovir Med Pediatr Oncol 2002;38:240-6.
- Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. Pharmacotherapy 2011;31:164-92.
- Allen Jr LV, Erickson III MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health Syst Pharm 1996;53:1944-9.
Ethical Compliance & Review Process
- •All submissions are screened under plagiarism detection.
- •Review follows editorial policy.
- •Authors retain copyright.
- •Peer Review Type: Double-Blind Peer Review
- •Published on: Jun 22 2026
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. You are free to share and adapt this work for non-commercial purposes with proper attribution.